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Background
Cyclic GMP producing soluble guanylyl cyclase (sGC) is
highly activated by the binding of nitric oxide (NO)
messenger to its heme. Besides NO, other NO-indepen-
dent molecules were shown to activate sGC. These
include a class of heme-replacers (e.g., protoporphyrin
IX and structurally unrelated activators BAY 58-2667
and HMR1766) or sGC stimulators (e.g., BAY 41-2272
and YC-1 and aryl-acrylamide derivatives). The later
class requires heme and sensitize sGC to low NO con-
centrations. Collectively these data suggest that various
m o d e so fa l l o s t e r i cs G Cr e g u l a t i o na r ep o s s i b l ea n d
some may have not been identified yet.
Results
We screened a library of “off-patent” drugs and identi-
fied gemfibrozil (dimethylphenoxy-dimethylpentanoic
acid), an anti-hyperlipidemic fibrate, as NO-independent
sGC activator. Other tested fibrates (fenofibrate, clofi-
brate, bezafibrate, ciprofibrate) did not activate sGC.
Structure-activity studies using molecules with phenoxy
or dimethylpentanoic acid groups identified gemfibrozil
moieties strictly necessary for sGC activation. In good
agreement with the data on purified sGC, gemfibrozil
dose-dependently relaxed preconstricted rat aortic rings.
Consistent with direct sGC activation, endothelium
denudation did not affect the vasorelaxing properties of
gemfibrozil. Some of the sGC-activating gemfibrozil ana-
logues, also showed a slightly improved vasorelaxing
properties.
By evaluating the effect of gemfibrozil on the activity
of truncated catalytically active sGC mutants we deter-
mined that gemfibrozil requires the heme-binding
domain of sGC for its function. Enzymatic studies
showed that, in contrast to heme-dependent stimulators
BAY 41-2272 and YC-1, gemfibrozil does not affect the
EC50 for NO, but diminishes the extent of sGC activa-
tion by NO. In addition, gemfibrozil-dependent activa-
tion is additively enhanced by allosteric regulator BAY
41-2272, suggesting a non-overlapping binding site.
Gemfibrozil-dependent activation of sGC is stimulated
by the depletion of heme, analogous to the heme-repla-
cing BAY 58-2667 and HMR1766. However, in contrast
to heme-independent stimulators the extent of activa-
tion is not affected by oxidation of sGC heme. Competi-
tion data suggest that gemfibrozil binding site may
overlap with one of the heme-replacing stimulators.
Conclusion
T h e s ed a t ai n d i c a t et h a tg e m f i b r o z i lr e p r e s e n t san e w
class of sGC activators which may have a distinct mode
of action. These data also indicate that besides anti-lipi-
demic properties gemfibrozil and some of its analogues
may also affect vascular plasticity.
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